168 related articles for article (PubMed ID: 37657455)
1. [Histology-agnostic tumor treatment - a farewell to tumor entities?].
Kerle I; Heining C
Dtsch Med Wochenschr; 2023 Sep; 148(18):1174-1181. PubMed ID: 37657455
[TBL] [Abstract][Full Text] [Related]
2. The evolving landscape of tissue-agnostic therapies in precision oncology.
Subbiah V; Gouda MA; Ryll B; Burris HA; Kurzrock R
CA Cancer J Clin; 2024 May; ():. PubMed ID: 38814103
[TBL] [Abstract][Full Text] [Related]
3. Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group.
Vranic S; Basu GD; Hall DW; Gatalica Z
Acta Med Acad; 2022 Dec; 51(3):217-231. PubMed ID: 36799315
[TBL] [Abstract][Full Text] [Related]
4. Impact of tissue-agnostic approvals on management of primary brain tumors.
Ahluwalia MS; Khosla AA; Ozair A; Gouda MA; Subbiah V
Trends Cancer; 2024 Mar; 10(3):256-274. PubMed ID: 38245379
[TBL] [Abstract][Full Text] [Related]
5. The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer.
Iannantuono GM; Torino F; Rosenfeld R; Guerriero S; Carlucci M; Sganga S; Capotondi B; Riondino S; Roselli M
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955671
[TBL] [Abstract][Full Text] [Related]
6. EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection.
Capper D; Reifenberger G; French PJ; Schweizer L; Weller M; Touat M; Niclou SP; Euskirchen P; Haberler C; Hegi ME; Brandner S; Le Rhun E; Rudà R; Sanson M; Tabatabai G; Sahm F; Wen PY; Wesseling P; Preusser M; van den Bent MJ
Neuro Oncol; 2023 May; 25(5):813-826. PubMed ID: 36632791
[TBL] [Abstract][Full Text] [Related]
7. Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the 'NSCLC' of GI Oncology?
Gupta A; Kurzrock R; Adashek JJ
Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900367
[TBL] [Abstract][Full Text] [Related]
8. Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics.
Tateo V; Marchese PV; Mollica V; Massari F; Kurzrock R; Adashek JJ
Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111371
[TBL] [Abstract][Full Text] [Related]
9. Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications.
Gouda MA; Nelson BE; Buschhorn L; Wahida A; Subbiah V
Clin Cancer Res; 2023 Aug; 29(15):2753-2760. PubMed ID: 37061987
[TBL] [Abstract][Full Text] [Related]
10. If it's a target, it's a pan-cancer target: Tissue is not the issue.
Adashek JJ; Kato S; Sicklick JK; Lippman SM; Kurzrock R
Cancer Treat Rev; 2024 Apr; 125():102721. PubMed ID: 38522181
[TBL] [Abstract][Full Text] [Related]
11. ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling - a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial.
Kringelbach T; Højgaard M; Rohrberg K; Spanggaard I; Laursen BE; Ladekarl M; Haslund CA; Harsløf L; Belcaid L; Gehl J; Søndergaard L; Eefsen RL; Hansen KH; Kodahl AR; Jensen LH; Holt MI; Oellegaard TH; Yde CW; Ahlborn LB; Lassen U
BMC Cancer; 2023 Feb; 23(1):182. PubMed ID: 36814246
[TBL] [Abstract][Full Text] [Related]
12. Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature.
Bernocchi O; Sirico M; Corona SP; Strina C; Milani M; Cappelletti MR; Ferrero G; Ziglioli N; Cervoni V; Macchiavelli A; Roviello G; Generali D
Pharmaceuticals (Basel); 2021 Feb; 14(2):. PubMed ID: 33669326
[TBL] [Abstract][Full Text] [Related]
13. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.
Subbiah V; Wolf J; Konda B; Kang H; Spira A; Weiss J; Takeda M; Ohe Y; Khan S; Ohashi K; Soldatenkova V; Szymczak S; Sullivan L; Wright J; Drilon A
Lancet Oncol; 2022 Oct; 23(10):1261-1273. PubMed ID: 36108661
[TBL] [Abstract][Full Text] [Related]
14. Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers.
Boilève A; Verlingue L; Hollebecque A; Boige V; Ducreux M; Malka D
Expert Opin Investig Drugs; 2021 Apr; 30(4):401-409. PubMed ID: 33641556
[No Abstract] [Full Text] [Related]
15. The role of molecular testing in pancreatic cancer.
Zhen DB; Safyan RA; Konick EQ; Nguyen R; Prichard CC; Chiorean EG
Therap Adv Gastroenterol; 2023; 16():17562848231171456. PubMed ID: 37197396
[TBL] [Abstract][Full Text] [Related]
16. Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology report.
Christofyllakis K; Monteiro AR; Cetin O; Kos IA; Greystoke A; Luciani A
J Geriatr Oncol; 2022 Nov; 13(8):1071-1083. PubMed ID: 35525790
[TBL] [Abstract][Full Text] [Related]
17. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
18. Application of histology-agnostic treatments in metastatic colorectal cancer.
Sartore-Bianchi A; Agostara AG; Patelli G; Mauri G; Pizzutilo EG; Siena S
Dig Liver Dis; 2022 Oct; 54(10):1291-1303. PubMed ID: 35701319
[TBL] [Abstract][Full Text] [Related]
19. Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?
Weis LN; Tolaney SM; Barrios CH; Barroso-Sousa R
NPJ Breast Cancer; 2021 Sep; 7(1):120. PubMed ID: 34518552
[TBL] [Abstract][Full Text] [Related]
20. [Current Status and Challenges in Tumor Agnostic Treatment].
Komine K
Gan To Kagaku Ryoho; 2023 Jun; 50(6):657-661. PubMed ID: 37317595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
